CAMPATH-1H in the treatment of autoimmune cytopenias

By Marsh JCW   Gordon-Smith EC  

Cytotherapy, Vol. 3, Iss. 3, 2001-05 ,pp. : 189-195

Ashgate Publishing Ltd

Access to resources Recommend Favorite

CAMPATH-1M T-cell depleted BMT for SCID: long-term follow-up of 19 children treated 1987–98 in a single center

By Gennery AR   Dickinson AM   Brigham K   Barge D   Spickett GP   Curtis A   Spencer V   Jackson A   Cavanagh G   Carter V   Palmer P   Flood TJ   Cant AJ   Abinun M  

Cytotherapy, Vol. 3, Iss. 3, 2001-05 ,pp. : 221-232

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Impact on T-cell depletion and CD34⁺ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G

By Williams R.J.   Clarke E.   Blair A.   Evely R.   Hale G.   Waldmann H.   Brookes S.   Pamphilon D.H.  

Cytotherapy, Vol. 2, Iss. 1, 2000-01 ,pp. : 5-14

Ashgate Publishing Ltd

Access to resources Recommend Favorite

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation

By Kottaridis PD   Milligan DW   Chopra R   Chakraverty RK   Chakrabarti S   Robinson S   Peggs K   Verfuerth S   Pettengell R   Marsh JCW   Schey S   Mahendra P   Morgan GJ   Hale G   Waldmann H   De Elvira MC   Williams CD   Devereux S   Linch DC   Goldstone AH   MacKinnon S  

Cytotherapy, Vol. 3, Iss. 3, 2001-05 ,pp. : 197-201

Ashgate Publishing Ltd

Access to resources Recommend Favorite

CAMPATH-1 antibodies in stem-cell transplantation

By Hale G   Cobbold S   Novitzky N   Bunjes D   Willemze R   Prentice HG   Milligan D   MacKinnon S   Waldmann H  

Cytotherapy, Vol. 3, Iss. 3, 2001-05 ,pp. : 145-164

Ashgate Publishing Ltd

Access to resources Recommend Favorite